Extended Data Fig. 10: Survival analysis.

a, Survival based on clonal expansion patterns. Kaplan–Meier survival curves for PFS are shown for three clonal expansion signatures (rows) in each arm of a clinical trial (columns), in which patients are dichotomized by scores above (dotted lines) and below (solid lines) the median in each clinical trial. Plus symbols indicate censoring events. Hazard ratios (HR) and two-sided P values from a Cox proportional-hazards model on patients in both groups are shown, highlighted in red with the corresponding survival curve when P < 0.05. b, Survival based on expansion signatures in the context of CD8A expression. Kaplan–Meier plots for PFS are shown using both CD8A expression and expansion signature scores (rows) in each arm of a clinical trial (columns). Patients in each clinical trial were divided into four groups based on CD8A expression above (CD8A^high) or below (CD8A^low) the median and on expansion signature score above (signature^high) or below (signature^low) the median among all patients in the corresponding clinical trial. Patients with low CD8A expression and low expansion signature score were used as a control for each of the other three groups. Hazard ratios and two-sided P values are from a Cox proportional-hazards model on patients in each group, highlighted in red with the corresponding survival curve when P < 0.05. c, Survival based on dual-expanded and tumour multiplet signatures. Kaplan–Meier survival curves are plotted as in b, except that patients were divided into four groups based on dual-expanded clone signature above (D^high) or below (D^low) the median and on tumour multiplet signature above (T^high) or below (T^low) the median among all patients in the corresponding clinical trial.